A detailed history of Rafferty Asset Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 89,876 shares of PTGX stock, worth $3.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
89,876
Previous 75,270 19.4%
Holding current value
$3.53 Million
Previous $2.61 Million 54.87%
% of portfolio
0.01%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $492,514 - $691,301
14,606 Added 19.4%
89,876 $4.04 Million
Q2 2024

Aug 13, 2024

SELL
$24.66 - $34.8 $4.04 Million - $5.71 Million
-163,938 Reduced 68.53%
75,270 $2.61 Million
Q1 2024

May 13, 2024

BUY
$21.79 - $32.15 $1.56 Million - $2.3 Million
71,413 Added 42.56%
239,208 $6.92 Million
Q4 2023

Feb 13, 2024

SELL
$14.05 - $23.44 $2.56 Million - $4.28 Million
-182,486 Reduced 52.1%
167,795 $3.85 Million
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $1.08 Million - $1.53 Million
64,822 Added 22.71%
350,281 $5.84 Million
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $2.38 Million - $3.88 Million
132,072 Added 86.1%
285,459 $7.88 Million
Q1 2023

May 11, 2023

SELL
$10.78 - $25.38 $1.53 Million - $3.6 Million
-141,961 Reduced 48.07%
153,387 $3.53 Million
Q4 2022

Feb 13, 2023

SELL
$7.36 - $11.17 $379,680 - $576,226
-51,587 Reduced 14.87%
295,348 $3.22 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $257,045 - $382,952
32,703 Added 10.41%
346,935 $2.93 Million
Q2 2022

Aug 12, 2022

BUY
$7.06 - $25.52 $749,334 - $2.71 Million
106,138 Added 51.0%
314,232 $2.49 Million
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $987,795 - $1.53 Million
42,322 Added 25.53%
208,094 $4.93 Million
Q4 2021

Feb 10, 2022

BUY
$17.63 - $37.1 $1.7 Million - $3.59 Million
96,642 Added 139.8%
165,772 $5.67 Million
Q3 2021

Nov 10, 2021

BUY
$12.95 - $49.69 $387,697 - $1.49 Million
29,938 Added 76.39%
69,130 $1.23 Million
Q2 2021

Aug 10, 2021

SELL
$25.57 - $44.88 $940,566 - $1.65 Million
-36,784 Reduced 48.42%
39,192 $1.76 Million
Q1 2021

May 10, 2021

BUY
$19.02 - $31.15 $1.18 Million - $1.93 Million
62,102 Added 447.61%
75,976 $1.97 Million
Q4 2020

Feb 10, 2021

SELL
$18.49 - $25.13 $261,189 - $354,986
-14,126 Reduced 50.45%
13,874 $280,000
Q3 2020

Nov 13, 2020

BUY
$15.19 - $22.4 $425,320 - $627,200
28,000 New
28,000 $547,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.